Inhibitory effects of azelnidipine tablets on morning hypertension.

Abstract

BACKGROUND:

Morning hypertension is a risk factor for cardiovascular and cerebrovascular events. Furthermore, it is a useful measure for definitive diagnosis of hypertension, and patients who self-assess their own blood pressure (BP) in the morning tend to exhibit better compliance with antihypertensive medication than those who do not.

OBJECTIVE:

The objective of this analysis was to determine the BP- and pulse rate-lowering effects of azelnidipine, a long-acting dihydropyridine calcium antagonist administered once daily in the morning.

METHODS:

We conducted the Azelnidipine Treatment for Hypertension Open-label Monitoring in the Early morning (At-HOME) Study by surveying patients who were taking azelnidipine. According to the study protocol, high systolic BP (SBP) was defined as ≥135 mmHg when measured at home in the morning and ≥140 mmHg when measured at the clinic during the day. A total of 5,433 hypertensive patients, who were registered at 1,011 medical institutions across Japan, were enrolled in the study. Data obtained from 4,852 of these patients (mean age, 64.8 years; female, 52.9 %; previous medication with other antihypertensive agents used concomitantly with the present study agent, 45.5 %) were used for efficacy analysis.

RESULTS:

At baseline, the subjects' mean [± standard deviation] SBP/diastolic BP values at home in the morning, at the clinic during the day, and at home in the evening were 156.9 ± 16.4/89.7 ± 12.0, 157.5 ± 18.7/89.1 ± 13.3, and 150.2 ± 17.6/85.6 ± 12.2 mmHg, respectively. The mean pulse rates were 72.7 ± 10.7, 74.9 ± 11.2, and 72.5 ± 9.6 beats/min, respectively. Patients whose BP was defined as high accounted for 83.4 % of the study population, whereas 9.9 % had 'masked' hypertension, defined as SBP of ≥135 mmHg at home in the morning and <140 mmHg at the clinic. However, from 4 weeks after initiation of azelnidipine treatment till the end of the study at week 16, all three daily BP determinations were significantly (p < 0.0001) lowered, and pulse rates at home in the morning, at the clinic, and at home in the evening were similarly and significantly reduced (by -3.7 ± 8.0, -3.5 ± 9.5, and -3.5 ± 7.3 beats/min, respectively). Whereas achievement of home SBP of <135 mmHg in the morning was noted in only 6.6 % of patients before the start of azelnidipine treatment, this was noted in 43.3 % after 16 weeks. Meanwhile, achievement of clinic SBP of <140 mmHg was increased from 12.9 % of patients to 56.1 % of patients at the same timepoints. After azelnidipine treatment, 32.2 % of patients had well-controlled hypertension in both the home and clinic settings. Adverse drug reactions occurred in 2.92 % of patients (154/5,265). All adverse drug reactions were as expected for the calcium antagonist class of agents.

CONCLUSION:

These data suggest that azelnidipine controlled morning hypertension well. Furthermore, azelnidipine reduced pulse rates significantly.

• Authors: Kazuomi Kario, Yuki Sato, Masayuki Shirayama, Megumi Takahashi, Kazuhito Shiosakai, Katsutoshi Hiramatsu, Masahiro Komiya, Kazuyuki Shimada
• Journal: Drugs in R&D (Drugs R D) Vol. 13 Issue 1 Pg. 63-73 (Mar 2013) ISSN: 1179-6901 [Electronic] New Zealand
• PMID: 23512719 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Calcium Channel Blockers
• Dihydropyridines
• Tablets
• Azetidinecarboxylic Acid
• azelnidipine

Topics

• Aged
• Azetidinecarboxylic Acid (analogs & derivatives, pharmacology, therapeutic use)
• Blood Pressure (drug effects, physiology)
• Calcium Channel Blockers (pharmacology, therapeutic use)
• Circadian Rhythm (drug effects, physiology)
• Dihydropyridines (pharmacology, therapeutic use)
• Female
• Humans
• Hypertension (drug therapy, epidemiology, physiopathology)
• Male
• Middle Aged
• Registries
• Tablets
• Treatment Outcome